Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
08 janv. 2024 09h00 HE
|
Apellis Pharmaceuticals, Inc.
Approximately $114 million in preliminary fourth quarter SYFOVRE® revenue as strong launch continuesApproximately $24 million in preliminary fourth quarter EMPAVELI® revenue WALTHAM, Mass., Jan. ...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 janv. 2024 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 2 new employees with a grant...
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on...
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
28 déc. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite...
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
14 déc. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for...
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
11 déc. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNHMajority of patients remained transfusion free over the long termZero cases of meningococcal...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 déc. 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company approved the grant of equity awards to 4 new employees with a grant...
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
21 nov. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 nov. 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 20 new employees with a grant...
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
04 nov. 2023 13h37 HE
|
Apellis Pharmaceuticals, Inc.
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension studyWell-demonstrated safety profile consistent with previously reported...